Informations sur le produit
Flumatinib mesylate is a growth factor that binds to the c-Met receptor and inhibits cellular proliferation. It has been shown to be a potent inhibitor of the c-Met receptor, which may prevent the activation of downstream signal transduction pathways that cause cancer cells to grow. Flumatinib mesylate is used in combination with other medicines for the treatment of myelogenous leukemias and healthy Chinese patients with renal cell carcinoma. Flumatinib mesylate has been shown to have a genotoxic impurity effect on cells and it is structurally similar to imatinib, an anticancer drug that inhibits platelet-derived growth factor receptors.